GlobeNewswire·Nov 6, 2026, 8:30 AM ET

Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome

QNRX

Quoin Pharmaceuticals released the latest episode of its NETHERTON NOW video series featuring mother Kristi Kristofferson, her daughter Kodi (who has Netherton Syndrome), and pediatric dermatologist Moise Levy, MD.
Kodi was diagnosed shortly after birth when medical staff observed red knuckles, leading to a 10-day NICU stay & identification via hair microscopy & genetic testing.
The disease delayed Kodi's motor development due to pain, requiring occupational, physical, & speech therapy alongside myofascial treatment.
Daily life involves a painful morning & evening routine where the family soaks skin in wet towels & peels off layers, often resulting in tears.
Kodi's skin regenerates 20 to 30 times faster than an average child, necessitating a high-protein diet to support rapid cell turnover.
Kristi emphasizes the need for public & school education to address misunderstandings, bullying, & insensitive questions regarding the visible skin condition.
Quoin's investigational product QRX003 is currently in a Phase 2/3 clinical trial, with interim results in August showing statistical significance on primary & key secondary endpoints.
Quoin expects to complete full recruitment for the QRX003 study by the end of 2026 & plans to report topline data in the second quarter of 2027.
Netherton Syndrome is a rare genetic disorder caused by SPINK5 gene mutations that causes severe skin barrier dysfunction, scaling, & itching, with no currently FDA-approved therapies.
QRX003 is a topical serine protease inhibitor lotion that has received Orphan Drug, Rare Pediatric Disease, & Fast Track designations from the U.S. FDA.

Company: Quoin Pharmaceuticals, Inc.
Keywords: Nasdaq:QNRX, Quoin Pharmaceuticals, Inc., clinical trials, Netherton Syndrome, #stocks, dermatology, pediatric